Share：
Share this content in WeChat
X
[Chinese][PDF]70981
• Review •
Research and progress of magnetic resonance spectroscopy in diagnosis and radiotherapy of prostate cancer
LIU Xiao-hang  ZHOU Liang-ping 

DOI:10.3969/j.issn.1674-8034.2010.02.014.


[Abstract] Magnetic resonance spectroscopy (MRS) is an approach that can non-invasively detect the composition and content evolvement of some metabolic materials in vivo, reflecting the pathophysiological processes at the molecular level. We reviewed the literatures about MRS application in the diagnosis and radiotherapy of prostate cancer, as well as the recent progress in the prostate MRS technology.
[Keywords] Magnetic resonance spectroscopy；Prostatic neoplasms；Diagnosis；Radiotherapy

LIU Xiao-hang Department of Radiology, Cancer Hospital of Fudan University, Shanghai 200032, China

ZHOU Liang-ping* Department of Radiology, Cancer Hospital of Fudan University, Shanghai 200032, China

*Correspondence to: Zhou LP, E-mail: zhoulp-2003@163.com

Conflicts of interest   None.

Received  2010-01-25
Accepted  2010-03-10
DOI: 10.3969/j.issn.1674-8034.2010.02.014
DOI:10.3969/j.issn.1674-8034.2010.02.014.

[1]
Wang XY, Zhou LP, Ding JP, et al. Quantitative analysis of normal prostate with MRS in Chinese male adults. Chin J Med Imaging Technol, 2003,19(5):580-582.
[2]
Scheenen TW, Heijmink SW, Roell SA, et al. Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility. Radiology, 2007, 245:507-516.
[3]
Choi H, Ma J. Use of perfluorocarbon compound in the endorectal coil to improve MR spectroscopy of the prostate. AJR Am J Roentgenol, 2008,190:1055-1059.
[4]
Rosen Y, Bloch BN, Lenkinski RE, et al. 3T MR of the prostate: reducing susceptibility gradients by inflating the endorectal coil with a barium sulfate suspension. Magn Reson Med, 2007,57:898-904.
[5]
Carlani M, Mancino S, Bonanno E, et al. Combined morphological, [1H]-MR spectroscopic and contrast-enhanced imaging of human prostate cancer with a 3-Tesla scanner: preliminary experience. Radiol Med, 2008,113:670-688.
[6]
Scheenen TW, Gambarota G, Weiland E, et al. Optimal timing for in vivo 1H-MR spectroscopic imaging of the human prostate at 3T. Magn Reson Med, 2005,53:1268-1274.
[7]
Chen AP, Cunningham CH, Kurhanewicz J, et al. High-resolution 3D MR spectroscopic imaging of the prostate at 3 T with the MLEV-PRESS sequence. Magn Reson Imaging, 2006,24:825-832.
[8]
Chen AP, Cunningham CH, Ozturk-Isik E, et al. High-speed 3T MR spectroscopic imaging of prostate with flyback echo-planar encoding. J Magn Reson Imaging, 2007,25:1288-1292.
[9]
Kurhanewicz J, Vigneron DB, Hricak H, et al. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7 cm3) spatial resolution. Radiology, 1996,198:795-805.
[10]
Wang P, Guo YM, Liu M, et al. A meta-analysis of the accuracy of prostate cancer studies which use magnetic resonance spectroscopy as a diagnostic tool. Korean J Radiol, 2008,9:432-438.
[11]
Jung JA, Coakley FV, Vigneron DB, et al. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology, 2004,233:701-708.
[12]
Futterer JJ, Scheenen TW, Heijmink SW, et al. Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Invest Radiol, 2007,42:116-122.
[13]
Villeirs GM, Oosterlinck W, Vanherreweghe E, et al. A qualitative approach to combined magnetic resonance imaging and spectroscopy in the diagnosis of prostate cancer. Eur J Radiol, 2010,73(2):352-356.
[14]
Coakley FV, Kurhanewicz J, Lu Y, et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology, 2002,223:91-97.
[15]
Wang XZ, Wang B, Gao ZQ, et al. 1H-MRSI of prostate cancer: the relationship between metabolite ratio and tumor proliferation. Eur J Radiol, 2010,73:345-351.
[16]
Wang XY, Zhou LP, Li FY, et al. MR spectroscopy of prostate cancer: correlation study of metabolic characters with Gleason score. Chin J Radiol, 2006,40(11):1181-1184.
[17]
Yeung DK, Yang WT, Tse GM. Breast cancer: in vivo proton MR spectroscopy in the characterization of histopathologic subtypes and preliminary observations in axillary node metastases. Radiology, 2002,225:190-197.
[18]
Heijmink SW, Scheenen TW, Futterer JJ, et al. Prostate and lymph node proton magnetic resonance (MR) spectroscopic imaging with external array coils at 3 T to detect recurrent prostate cancer after radiation therapy. Invest Radiol, 2007,42:420-427.
[19]
Umbehr M, Bachmann LM, Held U, et al. Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis. Eur Urol, 2009, 55:575-590.
[20]
Kumar V, Jagannathan NR, Kumar R, et al. Correlation between metabolite ratios and ADC values of prostate in men with increased PSA level. Magn Reson Imaging, 2006,24:541-548.
[21]
Kim JK, Jang YJ, Cho G. Multidisciplinary functional MR imaging for prostate cancer. Korean J Radiol, 2009,10:535-551.
[22]
Reinsberg SA, Payne GS, Riches SF, et al. Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection. AJR Am J Roentgenol, 2007,188:91-98.
[23]
Futterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology, 2006,241:449-458.
[24]
Kurhanewicz J, Vigneron D, Carroll P, Coakley F. Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol, 2008,18:71-77.
[25]
Wu G, Zhao W. Progress of non-operative treatment for prostate cancer. Chinese Society of Clinical Oncology, 2007: 603-611.
[26]
Pickett B, Vigneault E, Kurhanewicz J, et al. Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. Int J Radiat Oncol Biol Phys,1999, 44(4):921-929.
[27]
van Lin EN, Futterer JJ, Heijmink SW, et al. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys,2006, 65(1):291-303.
[28]
Hanlon AL, Pinover WH, Horwitz EM, et al. Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys, 2001,50(4):845-849.
[29]
Pickett B, Ten Haken RK, Kurhanewicz J, et al. Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging. Int J Radiat Oncol Biol Phys, 2004, 59(3):665-673.
[30]
Pickett B, Kurhanewicz J, Coakley F, et al. Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys, 2004,60(4):1047-1055.

PREV Magnetic resonance imaging of intracranial tuberculosis
NEXT Fibrocartilaginous mesenchymoma of the left lower leg: one case report
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn